698PPhase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC). (23rd October 2018) - Decaens, T; Barone, C; Assenat, E; Wermke, M; Fasolo, A; Merle, P; Blanc, J F; Grando, V; Bruns, R; Straub, J; Zhao, C; Faivre, S